A guide to employer plans, Medicare Part D's weight-loss exclusion, Medicaid and paying cash, plus how added uses like sleep apnea open coverage.
Recap by typeshit. Full story at qz.com.
Prof Jeanne Lubbe and Discovery Health weigh in. Discovery says GLP-1 claims tripled from 2022 to 2025, with members claiming for 5.4 months on average.
Employers on the Andel marketplace set their own contribution toward Wegovy, the daily Wegovy pill and Wegovy HD, with manufacturer-direct pricing and no insurance involved.
Business Day says medicines endorsed by the WHO still aren't available to public sector patients. The drugs involved aren't named in the share.
A study of 288,907 insured people found other medical costs rose about 22 cents per drug dollar. Also covers Medicare's $245 Bridge price and employer cutbacks.
The rundown covers CagriSema, retatrutide, MariTide, VK2735 and Roche's enicepatide, which the company says cut weight by 15.5% on average in a mid-stage trial.
As more people stop taking GLP-1 drugs, Grocery Dive asks how supermarkets plan to serve shoppers whose appetites and habits shift again.
Loading…